Inst Diagnosti (INDISA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Inst Diagnosti stock CLP 1,768, price CLP 2,293, that is 22.9% below the price, quality 43 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 1,064 CLP – 2,803 CLP · fair‑value band 1,238 CLP – 2,299 CLP · the 2,293 CLP price screens above the 1,768 CLP fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Inst Diagnosti in your weekly email
Every Wednesday you see whether Inst Diagnosti is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Instituto de Diagnóstico S.A. provides health services in Chile.
Show moreShow less
It offers patient information and exams instruction, and online services; specialties services; and outpatient services including urgency, laboratory, imaging, vaccination, blood bank, outpatient procedures, and reproductive medicine unit.
The company also provides hospitalization services, such as maternity, adult and pediatric hospitalization, adult critical patient unit, pavilion and surgical procedures, neonatology, and robotic surgery; and telemedicine services comprising online consultation and rehabilitation.
In addition, it operates health centers, which includes metabolic surgery and nutrition, thyroid and parathyroid, physical medicine and rehabilitation, endometriosis, hemodynamics service, and dialysis centers, as well as provide insurance products.
Further, the company offers research and training services, as well as newborn, school, and accident agreements. Instituto de Diagnóstico S.A. was founded in 1961 and is headquartered in Providencia, Chile.
Stock analysis
Inst Diagnosti (INDISA) currently trades at 2,293 CLP, while our model-based Fair Value estimate is 1,768 CLP, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 2,023 CLP per share, and 5 of the 26 models we run sit above the 2,293 CLP price.
Bear case: the Dividend Discount group reads lowest at 197.33 CLP, and 21 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 1,238 CLP (bear) to 2,299 CLP (bull), the price of 2,293 CLP sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Inst Diagnosti reported revenue of 272B CLP in FY2025 versus 189B CLP in FY2021, a compound +9.6%/yr. Reported net income was 15.7B CLP in FY2025, compounding −6.7%/yr from FY2021.
Key figures
Market cap 352B CLP (≈ $361M) Small · P/E ratio 28.6 · P/S ratio 1.23 · EPS (TTM) 80.25 CLP · Net margin 4.4% · Return on equity 7.5% · Return on assets (EBIT) 4.9% (5-year average) · Operating margin 9.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −23%, INDISA screens richer than that median.
Fair Value models
Bear1,238 CLPFair Value 1,768 CLPBull2,299 CLP
Price 2,293 CLP · Downside -22.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (68.82 CLP per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Start year 2020 (pandemic). Over 10 years: +8.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in CLP ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in CLP: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ −5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 5%
⚠ Rate on operating basis: 2025 sits 103% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Chile: IMF forecast 3.0% a year to 2030, 4.5% from 2016 to 2025) that is about +8.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−22.9% · Below median
Profitability
Return on equity (12 months)7.5% · Below median
Return on assets3.8% · Below median
Net margin (12 months)4.4% · Below median
Operating margin (12 months)9.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)8.9% · Above median
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equity0.34× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)28.6× · Pricier than median
P/B1.70× · Cheaper than median
P/S (12 months)1.23× · Cheaper than median
Price / free cash flow (fiscal year)16.3× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Inst Diagnosti Fair Value". https://www.fairvalue-calculator.com/stock/INDISA
Frequently asked questions
Is Inst Diagnosti (INDISA) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 1,768 CLP versus a price of 2,293 CLP, about 23% lower (overvalued).
What is the fair value of INDISA?
Our model-based fair value for Inst Diagnosti is 1,768 CLP (as of Nov 5, 2026), built from audited fundamentals. The current price: 2,293 CLP.
What is the quality score of INDISA?
Inst Diagnosti has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inst Diagnosti (INDISA)?
Our model-based price target is the fair value of 1,768 CLP (as of Nov 5, 2026) from 26 valuation models. Cautious scenario 1,238 CLP, optimistic scenario 2,299 CLP. It is a calculation from audited fundamentals, not an analyst target.
What is the Inst Diagnosti stock forecast for 2026?
Our models put fair value at 1,768 CLP, about 23% lower versus a price of 2,293 CLP (overvalued). Cautious scenario 1,238 CLP, optimistic scenario 2,299 CLP. The calculation is refreshed regularly with new filings.
What is the revenue of Inst Diagnosti (INDISA)?
Inst Diagnosti reported trailing-twelve-month revenue of about 287B CLP (latest available figure, as of Nov 5, 2026).
What growth is priced into Inst Diagnosti (INDISA)?
For today's price to be fair in a discounted-cash-flow model, Inst Diagnosti would have to grow free cash flow by +11.3 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of INDISA use?
Our models discount Inst Diagnosti at 10.6 %: a base by market capitalisation (small), damped by beta 0.39, country premium for Chile. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Inst Diagnosti that is +11.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Inst Diagnosti (INDISA) delivered so far?
Over the past 5 years revenue at Inst Diagnosti grew +14.3 % a year. The price currently implies free-cash-flow growth of +11.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Inst Diagnosti (INDISA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Inst Diagnosti (+11.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Inst Diagnosti (INDISA)?
The free-cash-flow yield on the price is 6.15 %: that much free cash flow Inst Diagnosti produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Inst Diagnosti (INDISA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inst Diagnosti it is 1,768 CLP per share (as of Nov 5, 2026), against a price of 2,293 CLP. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Inst Diagnosti stock overvalued or undervalued in 2026?
As of Nov 5, 2026, INDISA trades above its calculated fair value: price 2,293 CLP, fair value 1,768 CLP, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDISA?
No. The price is what the market pays today (2,293 CLP); the fair value is what the company's own numbers justify (1,768 CLP). For Inst Diagnosti the two are 524.59 CLP per share apart. That gap is exactly why we show both numbers side by side.
How much is Inst Diagnosti worth?
The market values Inst Diagnosti at about 352B CLP (market capitalisation, as of Nov 5, 2026). Per share that is 2,293 CLP; our models calculate a fair value of 1,768 CLP per share.
What do the bullish and bearish scenarios say about INDISA?
Our models span a range for Inst Diagnosti: cautious scenario 1,238 CLP, base 1,768 CLP, optimistic 2,299 CLP per share (as of Nov 5, 2026, price 2,293 CLP). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDISA?
Inst Diagnosti trades at a price-to-earnings ratio of 28.6 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,768 CLP is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2018 to 2025), reported earnings: 24.7. Other multiples: P/B 1.7, P/S 1.2, EV/EBITDA 12.6.
How solid is the balance sheet of Inst Diagnosti (INDISA)?
Balance-sheet figures for Inst Diagnosti (as of Nov 5, 2026): return on equity 7.5%, debt of 0.34 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is INDISA from its 52-week high?
Inst Diagnosti trades at 2,293 CLP, about 18% below its 52-week high of 2,784 CLP and at the low of 2,293 CLP (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,768 CLP is for.
Which stocks are comparable to Inst Diagnosti?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inst Diagnosti stock attractive at the current price?
The data as of Nov 5, 2026: price 2,293 CLP, calculated fair value 1,768 CLP (−23%), Quality Score 43/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDISA calculated?
We run Inst Diagnosti through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,768 CLP builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Inst Diagnosti itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inst Diagnosti (INDISA)?
The closing price on Nov 6, 2026 was 2,293 CLP. Our model-based fair value is 1,768 CLP, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inst Diagnosti right now?
Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (1,238 CLP to 2,299 CLP) leaves room in how you read the outcome.
Key figures of Inst Diagnosti
How large is the market capitalisation of Inst Diagnosti (INDISA)?
The market capitalisation of Inst Diagnosti is 352B CLP (≈ $361M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Inst Diagnosti (INDISA)?
The price-to-sales ratio of Inst Diagnosti is 1.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Inst Diagnosti (INDISA)?
Earnings per share at Inst Diagnosti are 80.25 CLP (price ÷ EPS = P/E 28.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Inst Diagnosti (INDISA)?
The net margin of Inst Diagnosti is 4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Inst Diagnosti (INDISA)?
The return on equity (ROE) of Inst Diagnosti is 7.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inst Diagnosti (INDISA)?
On an EBIT basis the return on assets of Inst Diagnosti is 4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Inst Diagnosti (INDISA)?
The operating margin of Inst Diagnosti is 9.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Inst Diagnosti (INDISA)?
Revenue at Inst Diagnosti is growing +8.9% versus a year earlier (3y avg +12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Inst Diagnosti (INDISA)?
Earnings per share at Inst Diagnosti are growing −30.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Inst Diagnosti (INDISA) carry?
The net debt of Inst Diagnosti is 70.6B CLP (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Inst Diagnosti in the live analysis
One click puts Inst Diagnosti on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026